Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-19T03:27:19.494Z Has data issue: false hasContentIssue false
  • English
  • Français

HPA axis overactivity and the pathogenesis of depression

Published online by Cambridge University Press:  13 June 2014

Jogin H Thakore
Jogin H Thakore*
Affiliation:
St Bartholomew's Hospital, London EC1A 7BE, England
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Irish Journal of Psychological Medicine , Volume 13 , Issue 1 , March 1996 , pp. 3 - 5
Copyright
Copyright © Cambridge University Press 1996

References

1.Houk, JC. Control strategies in physiological systems. FASEB J 1988; 2: 97–107.CrossRefGoogle ScholarPubMed
2.Koob, GF, Bloom, FE. Corticotropin-releasing factor and behaviour. FASEB 1985; 44: 259–63.Google Scholar
3.Farese, RV. Phosphoinositide metabolism and hormone action. Endocr Rev 1983; 4: 78–95.CrossRefGoogle ScholarPubMed
4.Dallman, M, Akana, SF, Scibner, KA, et al. Stress, feedback and facilitation in the hypothalamo-pituitary adrenal axis. J Neuroendocrinol 1992; 4: 517–26.CrossRefGoogle ScholarPubMed
5.De Kloet, ER, Reul, JM. Feedback action and tonic influence of corticosteroids on brain function: a concept arising from the heterogeneity of brain receptor systems. Psychoneuroendocrinol 1987; 12: 83–105.CrossRefGoogle ScholarPubMed
6.Dinan, TG. Glucocorticoids and the genesis of depressive illness: a psychobiolgocial model. Br J Psychiatry 1994; 164: 365–71.CrossRefGoogle ScholarPubMed
7.Nemerhoff, CB, Widerlov, E, Bissette, G, et al.Elevated concentrations of corticotropin releasing factor like immunoreactivity in depressed patients. Science 1984; 226: 1342–4.CrossRefGoogle Scholar
8.Gold, PW, Goodwin, FK, Chrousos, GP. Clinical and biochemical manifestations of depression: relation to the neurobiology of stress (second of two parts). N Engl J Med 1986; 319: 413–20.CrossRefGoogle Scholar
9.Trimble, MR. Biological Psychiatry. Chichester: Wiley, 1988: 241–81.Google Scholar
10.Van der Kar, LD, Brownfield, MS. Serotonergic neurons and neuroendocrine function. N Pharmacol Sci 1993; 8: 202–7.Google Scholar
11.Osestram, Q, Verleunt, T, Zuiderwijk, J, et al.Effect of long term corticosteroid administration on rat pituitary growth hormone and prolactin. Acta Endocrinologica 1985; 108: 475–8.Google Scholar
12.De Kloet, ER, Sybesma, H, Reul, HMHM. Selective control of serotonin receptor capacity in raphe-hippocampal system. Neuroendocrinology 1986; 42: 513–21.CrossRefGoogle ScholarPubMed
13.Lopez-Calderon, A, Ariznavarreta, C. Calderon, MD, et al.Role of the adrenal cortex in chronic stress-induced inhibition of prolactin secretion in rats. J Endocrinol 1989; 120: 269–73.CrossRefGoogle Scholar
14.Di Scullio, A, Bluet, MT, Mounier, P, et al.Changes in anterior pituitary levels after serotonin 1A receptor stimulation. Endocrinology 1990; 127: 567–572.Google Scholar
15.Dickinson, SL, Kennett, GA, Cruzon, G. Reduced 5-hydroxytryptamine-dependent behaviour in rats following chronic corticosterone treatment. Brain Res 1985; 345: 10–8.CrossRefGoogle Scholar
16.Bagdy, G, Calogero, AE, Aulakh, CS, et al.Longterm Cortisol treatment impairs behavioural and neuroendocrine responses to 5-HT1 agonists in the rat. Neuroendocrinology 1989; 50: 241–7.CrossRefGoogle ScholarPubMed
17.Dinan, TG. The role of Cortisol in spontaneous and stimulated prolactin release. J Basic Clin Physiol Pharmacol (in press).Google Scholar
18.O'Keane, V, Dinan, TG. Prolactin and Cortisol responses to d-fenfluramine in major depression: evidence for dimished reponsivity of central serotonergic function. Am J Psychiatry 1991; 148: 1009–15.Google Scholar
19.Siever, LJ, Murphy, D, Slater, S, et al.Plasma prolactin following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. Life Sci 1984; 34: 1029–39.CrossRefGoogle ScholarPubMed
20.Heninger, GR, Charney, DS, Sternberge, DE. Serotonergic function in depression. Arch Gen Psychiatry 1984; 41: 398–402.CrossRefGoogle ScholarPubMed
21.Mitchell, P, Smythe, G. Hormonal responses to fenfluramine in depressed and control subjects. J Affect Dis 1990; 19: 43–51.CrossRefGoogle ScholarPubMed
22.Liposits, Z, Phelix, C, Paull, WK. Synaptic interactions of serotonergic axons and corticotropin-releasing factor synthesising neurons in the hypothalamic paraventricular nucleus of the rat. Histochemistry 1987; 86: 541–9.CrossRefGoogle ScholarPubMed
23.Jhanwar-Uniyal, M, Liebowitz, SF. Impact of circulating corticosterone on alpha-1 and alpha-2 noradrenergic receptors in discrete brain areas. Brain Res 1986; 368: 404–8.CrossRefGoogle ScholarPubMed
24.Pacak, K, Palkovits, M, Kvetnansky, R, et al.Catecholaminergic inhibition by hypercortisolaemia in the paraventricular nucleus of the conscious rat. Endocrinology 1995; 136: 4814–19CrossRefGoogle Scholar
25.Coupland, N, Glue, P, Nutt, DJ. Challenge tests: assessment of the noradrenergic and GABA systems in depression and anxiety disorders. 1992 Mol Asp Med; 13: 221–47.Google Scholar
26.Katona, CLE, Theodorou, AE, Davies, SI, et al.Platelet binding and neuroendocrine responses in depression. In: Deakin, JFW, editor. The biology of depression. London: Gaskell, 1986.Google Scholar
27.Dinan, TG, Barry, S. Responses of growth hormone to desipramine in endogenous and non-endogenous depression. Br J Psychiatry 1990; 156: 680–4.CrossRefGoogle ScholarPubMed
28.Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972; 13: 694–8.CrossRefGoogle Scholar
29.Hall, CRW, Popkin, MK, Stickney, SKet al.Presentation of the steroid psychosis. J Nerv Ment Dis 1979; 167: 229–36.CrossRefGoogle Scholar
30.Smyllie, HC, Connolly, CK. Incidence of serious complications of corticosteroid theapy in respiratory disease. Thorax 1968; 23: 571–8.CrossRefGoogle Scholar
31.Wolkowitz, OM, Rubinow, D, Doran, AR, et al.Prednisone effects on neurochemistry and behaviour. Arch Gen Psychiatry 1990; 47: 963–8.CrossRefGoogle Scholar
32.Murphy, BEP. Steroids and depression. J Steroid Biochem Molec Biol 1991; 38: 537–59.CrossRefGoogle ScholarPubMed
33.Dorn, LD, Burgess, ES, Dubbert, Bet al.Psychopathology in patients with endogenous Cushing's syndrome: ‘atypical’ or melancholic features ? Clin Endocrinol 1995; 43: 433–42.CrossRefGoogle ScholarPubMed
34.De Kloet, ER. Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol 1992; 12: 95–164.Google Scholar
35.Jeffcoate, WJ, Silverstone, TJ, Edwards, CRW, et al.Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma Cortisol. Quart J Med 1979; 48: 465–72.Google ScholarPubMed
36.Starkman, MN, Scheingart, DE, Schork, MA. Cushing's syndrome after treatment; changes in Cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res 1986; 17: 177–88.CrossRefGoogle Scholar
37.Ribeiro, SCM, Tandon, R, Grunhaus, L, et al.The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 1993; 150: 1618–29.Google ScholarPubMed
38.Holsboer-Trachsler, E, Stohler, R, Hatzinger, M. Repeated administration of the combined dexamethasone/hCRH stimulation test druing the treatment of depression. Psychiatry Res 1991; 38: 163–71.CrossRefGoogle Scholar
39.Holsboer-Trachsler, E, Hemmeter, U, Hatzinger, M, et al.Sleep and bright light as potential augmenters of antidepressant drug treatment, neurobiological and psychometric assessment of course. J Pscyhiatry Re 1994; 28: 381–99.CrossRefGoogle Scholar
40.Thakore, JH, Dinan, Tg. Cortisol synthesis inhibion: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 1995; 37: 364–8.CrossRefGoogle Scholar
41.Rubin, RT, Phillips, JJ, Sadow, TF, et al.Adrenal Gland volume in major depression: increase during the depressive episode and decrease with successful treatment. Arch Gen Psychiatry 1995; 52: 213–8.CrossRefGoogle ScholarPubMed
42.Dinan, TG. Glucocorticoids and the genesis of depressive illness: a psychobiological model. Br J Psychiatry 164: 365–71.CrossRefGoogle Scholar
43.Barden, N, Reul, JMHM, Holsber, F. Do antidepressants stabilise mood through actions on the hypothalamic-pituitary-adrenocoritcal system? Trends Neursci 195; 18: 6–11.CrossRefGoogle Scholar
44.Montokowski, A, Barden, N, Wotjak, C, et al.Longt-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. Neuroendocrinol 1995; 7: 841–845.CrossRefGoogle Scholar
45.Murphy, BEP. Dhar, V, Ghadirian, Am, et al.Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol 1991; 11: 121–6.Google ScholarPubMed
46.Murphy, BEP. Treatment of major depression with steroid suppressive drugs. J Steroid Biochem Molec Biol 1991; 39: 239–44.CrossRefGoogle ScholarPubMed
47.Wolkowitz, OM, Reus, VI, Manfredi, F, et al.Ketoconazole administration in hypercortisolaemic patients. Am J Psychiatry 1993; 150: 810–12.Google Scholar
48.Thakore, JH, Dinan, TG. Effect of fluoxetine on dexamethasone-induced growth hormone responses in depression: a double-blind placebo-controlled study. Am J Psychiatry 1995; 152: 616–8.Google ScholarPubMed
49.O'Dwyer, AM, Lightman, S, Marks, MN, et al.Treatment of major depression with metyrapone and hydrocortisone. J Affect Disord 1995; 33: 123–8.CrossRefGoogle ScholarPubMed
50.Krishnan, KRR, Reed, D, Wilson, WHet al.RU486 in depression. Prog Neuro-Psychopharmacol Biol Psychiatry 1992; 16: 913–20.CrossRefGoogle ScholarPubMed
51.Murphy, BEP, Filipini, D, Gharidian, AM. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU486. J Psychiatry Neurosci 1993; 18: 209–13.Google Scholar
52.Arana, GW. Intravenous dexamethasone for symptoms of major depressive disorder. Am J Psychiatry (letter) 1991; 10: 1401–2.Google Scholar
53.Arana, GW, Forbes, R. Dexamethasone for the treatment of depression: a preliminary report. J Clin Psychiatry 1991; 52: 304–6.Google ScholarPubMed
54.Arana, GW, Santos, AB, Laraia, MT, et al.Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am J Psychiatry 1995; 152: 265–7.Google ScholarPubMed